The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
Transcriptomics confirms IRF1 as a key regulator of pyroptosis in diabetic retinopathy
This study aimed to establish an in vitro model of diabetic retinopathy by culturing human retinal endothelial cells (HREC) with high glucose (30 mmol/L), and to detect their transcriptome expression by RNA-seq, screen for key genes related to pyroptosis, and validate the sequencing results by subsequent experiments.METHODS: We used RNA-seq to detect the transcriptome expression differences between HREC cells cultured with high glucose and control group, and identified differentially expressed genes by GO/KEGG analysis. We constructed a PPI network and determined the key genes by Cytoscape software and CytoHubba plugin. We...
Source: Biochemical and Biophysical Research communications - March 30, 2024 Category: Biochemistry Authors: Yang Xian Xingli Wang Yong Yu XiaoLong Chen Source Type: research
Transcriptomics confirms IRF1 as a key regulator of pyroptosis in diabetic retinopathy
This study aimed to establish an in vitro model of diabetic retinopathy by culturing human retinal endothelial cells (HREC) with high glucose (30 mmol/L), and to detect their transcriptome expression by RNA-seq, screen for key genes related to pyroptosis, and validate the sequencing results by subsequent experiments.METHODS: We used RNA-seq to detect the transcriptome expression differences between HREC cells cultured with high glucose and control group, and identified differentially expressed genes by GO/KEGG analysis. We constructed a PPI network and determined the key genes by Cytoscape software and CytoHubba plugin. We...
Source: Biochemical and Biophysical Research communications - March 30, 2024 Category: Biochemistry Authors: Yang Xian Xingli Wang Yong Yu XiaoLong Chen Source Type: research
